NCT01625702已完成不适用
Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer
Peking University1 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2012年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 138
- 试验地点
- 1
- 主要终点
- circulating tumor cells in blood
研究概览
简要总结
To identify the correlation of CTCs with clinical prognosis in advanced/metastatic gastric cancer. Confirm the presence of CTCs are sensitive for monitoring response to chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •* Having signed informed consent
- •* Age≥ 18 years old
- •* Histologically confirmed gastric adenocarcinoma
- •* Unresectable recurrent or metastatic disease
- •* Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 6 months
- •* Previous chemotherapy with capecitabine or cisplatin, if applicable, more than 12 months.
- •* Measurable disease according to the RECIST criteria
- •* Karnofsky performance status ≥60
- •* Life expectancy of ≥2 month
- •* No prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks
- •* ALT and AST\<2.5 times ULN (≤5 times ULN in patients with liver metastases)
- •* Serum albumin level ≥3.0g/dL
- •* Serum AKP \< 2.5 times ULN
- •* Serum creatinine \3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet\>100,000/mm3, Hb\>9g/dl
排除标准
- •Brain metastasis (known or suspected)
- •Previous systemic therapy for metastatic gastric cancer
- •Inability to take oral medication
- •Previous therapy targeting at angiogenesis or vasculogenesis pathway or other targeted therapy
- •Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry Contraindications of nuclear magnetic resonance image such as fitment of cardiac pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball and so on.
- •Allergic constitution or allergic history to protium biologic product or any investigating agents.
- •Severe heart disease or such history as recorded congestive heart failure, uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve disease, severe abnormal ECG findings, cardiac infarction , or retractable hypertension.
- •Pregnancy or lactation period
- •Any investigational agent within the past 28 days
- •Other previous malignancy within 5 year, except non-melanoma skin cancer
- •Previous adjuvant therapy with capecitabine+platinum,
- •Pre-existing neuropathy>grade 1
- •Legal incapacity
结局指标
主要结局
circulating tumor cells in blood
时间窗: every 6 weeks
次要结局
未报告次要终点
研究者
Shen Lin
Director of GI oncology
Peking University
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Circulating Tumor Cells (CTCs) in Advanced Gastric CancerGastric CancerNCT01848015Peking University200
已完成
不适用
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC PatientsNasopharyngeal NeoplasmsNCT02505139Sun Yat-sen University166
已完成
3 期
Circulating Tumor Cells (CTCs) A prognostic biomarker in Patients with Hepatocellular CarcinomaCirculating tumor cells, liquid biopsy, hepatocellular carcinoma, biomarkerHepatocellular carcinomaTCTR20211226001/A73
招募中
不适用
The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.CarcinomaNCT05752357Chang Gung Memorial Hospital150
已完成
不适用
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal CancerClear Cell Renal CancerCirculating Tumor CellsCirculating Endothelial CellsPrognostic BiomarkersPredictive BiomarkersNCT02499458Lawson Health Research Institute44